Factors Related to Disclosure and Nondisclosure of Dietary Supplements in Primary Care, Integrative Medicine, and Naturopathic Medicine

Jennifer R. Guzman, PhD1, Debora A. Paterniti, PhD2,3, Yihang Liu, MD, MA, MS4, Derjung M. Tarn, MD, PhD5,*

1Department of Anthropology, State University of New York at Geneseo, USA
2Department of Sociology, Sonoma State University, USA
3Departments of Internal Medicine and Sociology, University of California - Davis, USA
4United Healthcare Group, USA
5Department of Family Medicine, University of California – Los Angeles, USA

Abstract

Background: Patients infrequently disclose use of dietary supplements to providers. Little is known about factors that motivate patients to disclose supplement use. The study aimed to identify reported factors motivating patients’ disclosure and nondisclosure of dietary supplement use and explore differences based on type of supplement and provider practice.

Methods: Mixed methods study combining qualitative content analysis of semi-structured interviews with statistical analyses to assess differences in identified factors by provider practice type and supplement type. Seventy-eight English-speaking patients who reported taking 466 dietary supplements in the previous 30 days were recruited from primary care and Complementary and Alternative Medicine (CAM), and Integrative Medicine (IM) offices in Southern California.

Results: We identified nine themes related to disclosure and nine related to nondisclosure of dietary supplement use. Major themes were features of the office visit, circumstances in patient health and medical care, and provider/patient characteristics. The most commonly raised theme promoting disclosure of supplement use was provider inquiry. Patients associate disclosure with having concerns about a supplement but also with annual physical exams and some routine topics of discussion, including self-care, lab results, and new medication prescriptions. Themes related to nondisclosure included lack of provider inquiry, features of the office visit, such as supplements...
being unrelated to the visit purpose, and patients’ convictions that supplements are safe or not important to discuss. Themes did not vary by supplement type. Primary care patients were more likely than CAM/IM patients to attribute nondisclosure to convictions that supplements were beneficial, not worth mentioning, or equivalent to food (p ≤0.001).

Conclusions: When providers fail to ask directly about dietary supplement use, disclosure is often an impromptu decision that is driven by the content of provider-patient interactions. Ensuring disclosure of dietary supplement use to prevent potential drug-supplement interactions or adverse health outcomes likely requires consistent, proactive provider queries about supplement use.

Keywords
Physician-patient relations; Communication; Dietary supplements; Patient disclosure; Qualitative research

Introduction
In the United States, dietary supplements are a pervasive form of preventative, adjunctive, and alternative healthcare [1–10]. More than half of US adults use dietary supplements, among whom 12% report using five or more products [4]. Concurrent use with prescription medications is high [6,9,11]. Some supplements may provide health benefits [12–14]. However, supplement use can result in serious adverse health outcomes such as renal and liver injury [7,15–24], particularly for patients with pre-existing liver or kidney disease [7,19]. Studies have shown that while rare, the most serious supplement-drug interactions can result in renal and liver toxicity, cardiotoxicity, cardiovascular collapse, hypovolemic shock, and even death [21–23]. Because of such risks, the Food and Drug Administration (FDA) recommends that patients consult with a healthcare professional before using supplements [25]. However, most patients take dietary supplements on their own, and infrequently disclose their use to healthcare providers [7,26–37].

Numerous studies have identified factors associated with nondisclosure of supplement use to conventional medical providers. Patients are less likely to disclose if a provider does not ask about supplement use [29,36,38,39] or when they perceive time constraints [27,29,36]. Patients also report nondisclosure when they feel their provider is disinterested, unresponsive, or unknowledgeable about supplements [26,27,29,36,38,41], or may disapprove or respond negatively to supplement use [26,27,29,36,38,40,41]. Others do not disclose because they feel it is unimportant [27,36,38,39] or that they already have the information they need [27].

Comparatively less is known about the circumstances that prompt patient disclosure of dietary supplement use. Conventional physicians’ queries about supplement use are associated with disclosure [27]. And patients are more likely to disclose Complementary and Alternative Medicine (CAM) use, including dietary supplements, if a professional recommended the supplement [42], if it was used to treat a medical condition [42], or if patients believed the provider was knowledgeable or open-minded about CAM [26,30,38]. Disclosure may also be motivated by the belief that disclosure is important for safety or to help others with the same condition [30].
The research literature lacks information about the specific reasons patients disclose dietary supplement use during a given office visit, and whether the types of supplements patients are taking influence whether they disclose their use. Patient reasons for disclosing or not disclosing to CAM/Integrative Medicine (IM) practitioners have not been studied at all. This study aims to (1) Explore patient reasons for disclosure and nondisclosure of dietary supplement use during a particular outpatient office visit, as well as generally, and (2) Determine whether those reasons vary by supplement type or provider specialty (conventional primary care versus CAM/IM doctors).

**Methods**

**Design**

The data are from a larger study concerning provider-patient communication about dietary supplements [43]. Between November 2011 and May 2013, 603 patients were recruited from 61 participating provider waiting rooms (32 primary care physicians from academic, community health, and managed care practices, 14 integrative medicine physicians from academic and private practices, and 15 CAM providers - 5 naturopaths, 5 acupuncturists, 5 chiropractors). Eligible patients were English or Spanish-speaking, at least 18 years old, and available to participate in a follow-up interview within one week of an audio-recorded office visit. Participants completed surveys about demographics and supplement use.

Among 477 of the 603 patients who reported taking dietary supplements in the past 30 days, 126 were purposively sampled for interviews based on practice type and supplement disclosure during their office visit. Eight of the 126 patients could not be reached, and one decided not to participate. Our analyses focused on 78 English-language interviews with patients of primary care and IM physicians and naturopathic physicians who held Naturopathic Doctor (ND) degrees. Since these providers all practice primary care [44–47], they may be more likely to solicit complete medication and supplement information than chiropractors and acupuncturists, who most frequently consult about more focused complaints [48–50]. Patients received a $25 gift card upon interview completion. The Institutional Review Boards of the University of California, Los Angeles and Kaiser Permanente approved the study protocol.

Trained and experienced interviewers--a medical anthropologist (JRG) and a medical linguist--conducted all patient interviews via telephone. Interviewers used one of two semi-structured interview guides [51] containing slightly different questions for interviewees who did and did not disclose supplement use during the recorded visit. Dietary supplements were defined for interviewees as “vitamins, minerals, and herbal supplements” [52]. We asked interviewees who disclosed supplement use about the circumstances and content of their discussions and their reactions to them (Table 1). Interviewees reporting nondisclosure were asked why, and what circumstances could have prompted disclosure. We asked all interviewees who should initiate discussions and when disclosure is necessary/unnecessary. We used follow-up probes [53] for clarification as needed. Interviews lasted an average of 29.7 (SD = 9.2) minutes and were digitally recorded and transcribed verbatim.
Categorization of supplements

Every supplement mentioned in the interviews was categorized into: (1) Supplements commonly recommended by primary care providers (i.e. calcium, vitamin D, fish oil/omega-3, folic acid, and glucosamine with/without chondroitin or methylsulfonylmethane), (2) Multivitamins/multiminerals, (3) All other vitamins/minerals, (4) Non-vitamins, non-minerals (NVNM) and (5) General, a category to capture comments interviewees made about disclosure and nondisclosure of supplements, regardless of type. The fifth category included cases where interviewees talked about circumstances in which they considered disclosure necessary or unnecessary. Our determination of disclosure or nondisclosure of each supplement was based on interviewee report during the interview.

Qualitative analysis

Each interview transcript was verified for accuracy prior to analysis. Two coders, a practicing primary care physician with research expertise in provider-patient communication (DMT) and a medical anthropologist (JRG), conducted inductive content analysis [54] on a subset of interviews, (1) Identifying themes related to disclosure or nondisclosure of each supplement interviewees were taking and of supplements in general and (2) Categorizing themes and subthemes. A medical sociologist with expertise in qualitative methods (DAP) reviewed a partially overlapping set of transcripts and an additional set of transcripts for validity of coding. They also worked together to finalize the coding scheme and develop a codebook defining each theme.

One investigator (JRG) coded all interviews, one of the other two investigators double-coded 20 interviews (26%), and all three investigators coded six interviews (8%). Multiple investigators coded at least 10% of the interviews from each practice type. Throughout the coding process, the investigators iteratively reviewed the coding scheme and incorporated new themes until saturation was reached [55]. Coding discrepancies between auditors were discussed and resolved by group consensus with consideration of the decision’s relevance to clinical practice. Atlas.ti 7 (Scientific Software Development, Berlin, Germany) was employed for systematically storing, coding, retrieving, and reviewing coded data.

Statistical analysis

All statistical analyses were conducted using SAS, version 9.1. Summary statistics, including means and percentages, were calculated to describe participants’ characteristics. We used generalized linear mixed models to examine the relationship of themes identified through our qualitative analysis of the interviews on patient disclosure or nondisclosure of individual dietary supplements. Generalized linear mixed models were selected because they allow us to control for the possible correlation of behaviors within patients. For this analysis, any patient mention of a theme pertaining to disclosure or nondisclosure of dietary supplement use counted as fulfillment of the theme. We also used generalized linear mixed models to assess differences in mentions of themes related to dietary supplement disclosures and nondisclosures by practice types (conventional primary care versus integrative/naturopathic) and supplement type (supplements commonly recommended by primary care providers; multivitamins and multiminerals; all other vitamins and minerals; and NVNM).
Results

Patient and supplement characteristics

Of the 78 patients in the study, 45 were primary care, 23 were IM, and 10 were naturopathic patients. Patients were predominantly white, female, and highly educated. Compared to integrative and naturopathic patients, primary care patients had significantly lower educational achievement \((p = 0.02)\) and were younger and more ethnically diverse (though these differences were not statistically significant) (Table 2). Forty participants (51.2\%) reported disclosing at least one supplement to their provider during their office visit. Patients discussed between one and 18 supplements during their interviews (mean 6.0, SD = 3.7), and a total of 466 supplements across all interviews (39 multivitamin/multi-minerals, 101 supplements commonly recommended by primary care providers, 104 other vitamin/mineral supplements, and 222 NVNM). Of these, interviewees reported disclosing 156 (33\%) to their provider.

Themes promoting disclosure and nondisclosure

We identified twelve major themes related to disclosure/nondisclosure (Table 3), which spanned three domains: features of the office visit, patient health and medical care circumstances, and provider and patient characteristics. Interviewees mentioned six themes in relation to both disclosure and nondisclosure three in relation to disclosure only, and three in relation to nondisclosure only.

Themes promoting disclosure: The themes related to disclosure that emerged most frequently were related to features of the office visit. Many interviewees attributed their disclosure of supplement use to interaction during the visit, specifically provider inquiries. For example, “Doctor [surname] asked what supplements I take, and I just mentioned that I take that for heart and skin health” (688). Unprompted disclosures were most often attributed to discussion topics pertinent to supplement use, e.g. patient self-care and laboratory results. As one interviewee explained, “When he was asking me about sleep, I immediately mentioned that I had been using the melatonin” (234). Occasionally, interviewees associated visit characteristics with disclosure, i.e. pre-surgery visits, physical examinations, or new patient visits.

Many interviewees associated aspects of patient health and medical care circumstances with disclosure. Having concerns about a supplement, including perceived or feared side effects and questions about safety, commonly emerged. Few reported actual concerns, but many said they would disclose if they had them, or to get advice. Some interviewees said patients should disclose when taking unusual or multiple supplements, mega-dosing, or changing a supplement regimen (circumstances of supplement use). Many interviewees believed that disclosure was important under medication-related circumstances; for example, “It needs to be brought up any time that there’s going to be a prescription that’s not something you’ve taken before” (172). A minority of interviewees said disclosure is necessary when patients have medical conditions (“I have a lot of medical problems, so I always, every time I see her, I just kind of put her up to date” (838)).
Finally, interviewees occasionally cited provider and patient characteristics. Several noted that provider characteristics like expertise/knowledgeability or receptiveness to discussing supplements gave them confidence to disclose. A few interviewees conveyed personal convictions about the importance of disclosure.

**Themes promoting nondisclosure:** Most interviewees invoked multiple themes concerning nondisclosure. Numerous interviewees attributed nondisclosure to interaction *during the visit*, specifically the topic not coming up. Frequently mentioned visit characteristics associated with nondisclosure include when supplements are unrelated to the visit’s purpose, when there are competing demands or time constraints, or when they thought the visit type did not warrant disclosure (i.e. follow-up and acute care visits). Nondisclosure was also attributed to organizational or procedural factors: when the patient is unprepared to discuss supplement use or believes the provider already knows about their supplement use.

Nondisclosure was often associated with the circumstances of supplement use: sporadic use, long duration of use, or use of a supplement considered to be safe. One patient taking Coenzyme Q10 noted “I thought that’s very safe to take, and so I didn’t discuss it with my doctor” (565). For others, good health or fitness (medical condition) made discussion unnecessary (e.g., “I wouldn’t really feel the need to tell him because I’m in relatively good shape” (151)).

According to some interviewees, provider characteristics militated against disclosure: lack of relevant expertise, unreceptiveness to supplement discussions, and prejudice against supplements. Others attributed nondisclosure to convictions about supplements: they aren’t worth mentioning, are beneficial/commonplace, or are equivalent to food nutrition. One patient explained, “Usually I talk to him about everything. But just being a vitamin, I didn’t feel it [was] necessary” (156). Some interviewees expressed confidence in their own knowledge about supplements. Finally, some reported that supplements *did not cross their mind* during the office visit (“It’s not a decision not to bring them up. It’s more just not really thinking about it” (560)).

**Statistical differences in disclosure and nondisclosure of supplements**

Statistical analyses revealed that interviewees reported disclosing supplement use less frequently to primary care physicians (13% of supplements) than to integrative/naturopathic practitioners (45%) (p < 0.01). Five of the nine themes related to disclosure were significantly associated with reported disclosure (Table 4): Interaction during the visit (p < 0.001), discussion topic (p < 0.001), patient concerns about supplement (p < 0.01), medication related (p < 0.001), and provider characteristics (p < 0.001). Visit characteristics, circumstances of supplement use, and medical conditions were not significantly related to reported disclosure. Six themes related to nondisclosure of supplement use were significantly associated with reported nondisclosure: interaction during the visit (p ≤0.01), visit characteristics (p < 0.001), organizational and procedural factors (p < 0.001), circumstances of supplement use (p < 0.01), provider characteristics (p = 0.04), patient
convictions (p ≤0.001), and did not cross mind (p ≤0.001). Medical condition and patient confidence were not significantly related to reported nondisclosure.

There were no differences in the frequency with which patients of primary care and integrative/naturopathic providers mentioned themes promoting dietary supplement disclosure. However, primary care patients were more likely than integrative/naturopathic patients to raise several themes associated with nondisclosure of specific supplements (data not shown): circumstances of supplement use (SE 1.36, p = 0.02), medical condition (SE 5.81, p = 0.03), patient convictions (SE 1.84, p ≤0.001), and patient confidence (SE 8.13, p = 0.03). There were no differences in how often patients raised themes about disclosure and nondisclosure based on supplement type.

Discussion

This study expands existing knowledge about patients’ motivations for disclosing dietary supplement use to primary care, integrative medicine, and naturopathic providers. Findings reveal several factors promoting disclosure that have not been previously identified in the literature. Previous research suggests that a provider’s “communication style [30]” (i.e. receptive/non-judgmental versus discouraging/critical) is a moderating factor of disclosure. However, this study suggests that disclosure is often an impromptu decision driven by unfolding interactional opportunities. Nondisclosure may be the default practice for most patients, who typically fail to think about their supplement use during visits and who disclose only when they have a specific concern or a certain threshold of relevance to the topic-at-hand is reached. Patients associate disclosure with out-of-the-ordinary circumstances, such as having concerns about a supplement they are taking or when mega-dosing. However, patients also associate disclosure with certain more routine topics of discussion, including talk about health problems the patient is treating with supplements and lab results they believe may be influenced by supplement use. Patients also view disclosure as warranted when a new medication is being prescribed. Some types of office visits are viewed as more appropriate occasions for disclosing dietary supplement use than others, specifically annual physicals and new patient appointments versus acute care and follow-up visits.

Physician awareness of the circumstances patients associate with disclosure may enable them to better foster disclosure and discussion of supplement use. If a patient discloses use of a dietary supplement during a discussion of laboratory results, for example, the physician may be able to use the opportunity as an interactional wedge to ask about other supplement use, producing a sort of domino effect for disclosure. To take advantage of factors that promote disclosure, provider education to increase inquiries about supplement use, which other studies have recommended [26,27,29,33,34,38], could train doctors to target optimal occasions, as well as encouraging the sort of receptive communication style that facilitates patient trust and willingness to disclose. Taking advantage of interactional opportunities to pursue non-judgmental supplement discussions may serve as a way for doctors to dispel patient perceptions that providers are not interested in talking about dietary supplements [26,27,29,38,41] and to convey why disclosure is vital for ensuring patient health by
mitigating potential adverse interactions and health outcomes, particularly in patients with pre-existing medical conditions [7,19].

Several factors associated with nondisclosure were more prevalent in primary care than integrative/naturopathic settings, suggesting that conventional primary care doctors face greater challenges to learning what supplements their patients are taking. These challenges include several patient convictions: that supplements are beneficial, commonplace, or equivalent to nutrition from food and that these characteristics make disclosure unnecessary. Other factors associated with nondisclosure that may disproportionately affect primary care practitioners include patients’ confidence in their own good health and their knowledge about the supplements they are taking. Across practice types, patients do not appear to distinguish between products that may require consultation with a healthcare professional (e.g., herbal NVNM supplements, which may interact with prescription medications) and those that do not. Possible interventions to promote disclosure of dietary supplement use may include patient education about the risks of supplement-medication interactions and the importance of disclosing supplement use. Such interventions could be targeted to patients who take prescription medications or have chronic conditions that make supplement use particularly risky [7,19,56–58]. Interventions targeted to providers could also emphasize the importance of inquiring about supplement use with these kinds of patients during chronic care visits and visits when changes are made to patient medication regimens.

The findings of this study are limited by the study population. The study sample was small and non-random, recruited exclusively in urban Southern California and overrepresented individuals with high educational achievement and non-Hispanic whites, who may not be representative of all dietary supplement users. Because use of dietary supplements varies across racial/ethnic groups, and disclosure rates for minorities are very low [4,32,34,42,59–62], further study of factors related to disclosure in these populations is warranted. Findings regarding disclosure are also limited because they rely on patient recall. Study of office visit recordings and transcripts is warranted to identify patterns in actual disclosure and nondisclosure.

In conclusion, the findings of this study suggest that promoting effective discussions about supplement use between patients and providers during office visits requires more than eliminating obstacles to disclosure and likely requires a proactive stance on the part of providers to inquire about supplement use and to pursue discussions when patients raise the topic. Given the typicality of nondisclosure, asking direct questions about a patient’s supplement use may be the most reliable way for providers to learn what a patient is taking. Posing questions in the contexts that patients associate with disclosure may help to maximize their effectiveness, and providers may need to address a range of patient convictions that militate against disclosure. Initiating discussion about supplement use may align with patient expectations about dietary supplement discussions [63], improve patient satisfaction [64,65] and provider-patient relations [66], and set a positive precedent for disclosure in the future.
Acknowledgments

We thank Amanda McArthur for her editorial assistance with this manuscript. We also thank Peter S. Khang, MD at Kaiser Permanente, and Lyndee Knox, at LA Net Community Resource Network for leading participant recruitment for the study at their respective sites. This work was supported by grant R01AT005883 from the National Center for Complementary and Integrative Health and the Office of Dietary Supplements. The contents of the work are solely the responsibility of the authors and do not necessarily represent the official views of the National Center for Complementary and Integrative Health, the Office of Dietary Supplements, or the National Institutes of Health.

References

1. Kiefer DS, Chase JC, Love GD, Barrett BP (2014) The overlap of dietary supplement and pharmaceutical use in the midus national study. Evid Based Complement Alternat Med: eCAM 823853 eCAM 823853. [PubMed: 24834100]

2. Bailey RL, Gahche JJ, Miller PE, Thomas PR, Dwyer JT (2013) Why US adults use dietary supplements. JAMA Intern Med 173: 355–361. [PubMed: 23381623]

3. Ben-Arye E, Attias S, Levy I, Goldstein L, Schiff E (2017) Mind the gap: Disclosure of dietary supplement use to hospital and family physicians. Patient Educ Couns 100: 98–103. [PubMed: 27516439]

4. Cowan AE, Jun S, Gahche JJ, Tooze JA, Dwyer JT, et al. (2018) Dietary supplement use differs by socioeconomic and health-related characteristics among U.S. adults, NHANES 2011–2014. Nutrients 10.

5. Ford K, Whiting SJ (2018) Vitamin and mineral supplement use by community-dwelling adults living in Canada and the United States: A scoping review. J Diet Suppl 15: 419–430. [PubMed: 28837388]

6. Gahche JJ, Bailey RL, Potischman N, Dwyer JT (2017) Dietary supplement use was very high among older adults in the United States in 2011–2014. J Nutr 147: 1968–1976. [PubMed: 28855421]

7. Henson JB, Brown CL, Chow SC, Muir AJ (2017) Complementary and alternative medicine use in United States adults with liver disease. J Clin Gastroenterol 51: 564–570. [PubMed: 27479144]

8. Kantor ED, Rehm CD, Du M, White E, Giovannucci EL (2016) Trends in dietary supplement use among US adults from 1999–2012. JAMA 316: 1464–1474. [PubMed: 27727382]

9. Qato DM, Wilder J, Schumm LP, Gillet V, Alexander GC (2016) Changes in prescription and over-the-counter medication and dietary supplement use among older adults in the United States, 2005 vs 2011. JAMA Intern Med 176: 473–482. [PubMed: 26998708]

10. Wu CH, Wang CC, Tsai MT, Huang WT, Kennedy J (2014) Trend and pattern of herb and supplement use in the United States: results from the 2002, 2007, and 2012 national health interview surveys. Evid Based Complement Alternat Med 2014: 872320.

11. Agbabiaka TB, Wider B, Watson LK, Goodman C (2017) Concurrent use of prescription drugs and herbal medicinal products in older adults: A systematic review. Drugs Aging 34: 891–905. [PubMed: 29196903]

12. Dong JY, Qin LQ, Zhang Z, Zhao Y, Wang J, et al. (2011) Effect of oral L-arginine supplementation on blood pressure: a meta-analysis of randomized, double-blind, placebo-controlled trials. Am Heart J 162: 959–965. [PubMed: 22137067]

13. Kris-Etherton PM, Harris WS, Appel LJ (2002) Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 106: 2747–2757. [PubMed: 12438303]

14. Shagghahi AM, Abuweiss SS, Jones PJ (2013) Cholesterollowering efficacy of plant sterols/stanols provided in capsule and tablet formats: results of a systematic review and meta-analysis. J Acad Nutr Diet 113: 1494–1503. [PubMed: 24144075]

15. Brown AC (2017) Kidney toxicity related to herbs and dietary supplements: Online table of case reports. Part 3 of 5 series. Food Chem Toxicol 107: 502–519. [PubMed: 28755953]

16. Chatham-Stephens K, Taylor E, Chang A, Peterson A, Daniel J, et al. (2017) Hepatotoxicity associated with weight loss or sports dietary supplements, including OxyELITE Pro United States, 2013. Drug Test Anal 9: 68–74. [PubMed: 27367536]
17. de Boer YS, Sherker AH (2017) Herbal and dietary supplement-induced liver injury. Clin Liver Dis 21: 135–149. [PubMed: 27842768]

18. Geller AI, Shehab N, Weidle NJ, Lovegrove MC, Wolpert BJ, et al. (2015) Emergency department visits for adverse events related to dietary supplements. New Engl J Med 373: 1531–1540. [PubMed: 26465986]

19. Grubbs V, Plantinga LC, Tuot DS, Hedgeman E, Saran R, et al. (2013) Americans’ use of dietary supplements that are potentially harmful in CKD. Am J Kidney Dis 61: 739–747. [PubMed: 23415417]

20. Navarro VJ, Khan I, Bjornsson E, Seeff LB, Serrano J, et al. (2017) Liver injury from herbal and dietary supplements. Hepatology 65: 363–373. [PubMed: 27677775]

21. Parvez MK, Rishi V (2019) Herb-Drug interactions and hepatotoxicity. Curr Drug Metab 20: 275–282. [PubMed: 30914020]

22. Posadzki P, Watson L, Ernst E (2013) Herb-drug interactions: an overview of systematic reviews. Br J Clin Pharmacol 75: 603–618. [PubMed: 22670731]

23. Ronis MJ, Pederson KB, Watt J (2018) Adverse effects of nutraceuticals and dietary supplements. Annu Rev Pharmacol Toxicol 58: 583–601. [PubMed: 28992429]

24. Vega M, Verma M, Beswick D, Bey S, Hossack J, et al. (2017) The incidence of drug and herbal and dietary supplement-induced liver injury: preliminary findings from gastroenterologist-based surveillance in the population of the state of Delaware. Drug Saf 40: 783–787. [PubMed: 28553626]

25. Administration USFaD (2008) FDA 101: Dietary supplements. FDA Consumer Health Information.

26. Adler SR, Fosket JR (1999) Disclosing complementary and alternative medicine use in the medical encounter: a qualitative study in women with breast cancer. J Fam Pract 48: 453–458. [PubMed: 10386489]

27. Busse JW, Heaton G, Wu P, Wilson KR, Mills EJ (2005) Disclosure of natural product use to primary care physicians: a cross-sectional survey of naturopathic clinic attendees. Mayo Clin Proc 80: 616–623. [PubMed: 15887429]

28. Chiba T, Sato Y, Suzuki S, Umegaki K (2015) Concomitant use of dietary supplements and medicines in patients due to miscommunication with physicians in Japan. Nutrients 7: 2947–2960. [PubMed: 25894658]

29. Davis EL, Oh B, Butow PN, Mullan BA, Clarke S (2012) Cancer patient disclosure and patient-doctor communication of complementary and alternative medicine use: a systematic review. Oncologist 17: 1475–1481. [PubMed: 22933591]

30. Foley H, Steel A, Cramer H, Wardle J, Adams J (2019) Disclosure of complementary medicine use to medical providers: a systematic review and meta-analysis. Scientific Reports 9: 1573. [PubMed: 30733573]

31. Jou J, Johnson PJ (2016) Nondisclosure of complementary and alternative medicine use to primary care physicians: findings from the 2012 national health interview survey. JAMA Internal Medicine 176: 545–546. [PubMed: 26999670]

32. Kennedy J, Wang CC, Wu CH (2008) Patient disclosure about herb and supplement use among adults in the U.S. Evid Based Complement Alternat Med 5: 451–456. [PubMed: 18955213]

33. McCrea CE, Pritchard ME (2011) Concurrent herb-prescription medication use and health care provider disclosure among university students. Complement Ther Med 19: 32–36. [PubMed: 21296265]

34. Mehta DH, Gardiner PM, Phillips RS, McCarthy EP (2008) Herbal and dietary supplement disclosure to health care providers by individuals with chronic conditions. J Altern Complement Med 14: 1263–1269. [PubMed: 19032071]

35. Mikhail N, Wali S, Ziment I (2004) Use of alternative medicine among Hispanics. J Altern Complement Med 10: 851–859. [PubMed: 15650475]

36. Robinson A, McGrail MR (2004) Disclosure of CAM use to medical practitioners: a review of qualitative and quantitative studies. Complement Ther Med 12: 90–98. [PubMed: 15561518]
37. Samuels N, Zisk-Rony RY, Zevin S, Becker EL, Yinnon AM, et al. (2012) Use of non-vitamin, non-mineral (NVNM) supplements by hospitalized internal medicine patients and doctor-patient communication. Patient Educ Counsel 89: 392–398.

38. Vickers KA, Jolly KB, Greenfield SM (2006) Herbal medicine: women’s views, knowledge and interaction with doctors: a qualitative study. BMC Complement Altern Med 6: 40. [PubMed: 17156416]

39. Young LA, Faurot KR, Gaylord SA (2009) Use of and communication about dietary supplements among hospitalized patients. J Gen Intern Med 24: 366–369. [PubMed: 19096896]

40. Blendon RJ, DesRoches CM, Benson JM, Brodie M, Altman DE (2001) Americans’ views on the use and regulation of dietary supplements. Arch Intern Med 161: 805–810. [PubMed: 11268222]

41. Tasaki K, Maskarinec G, Shumay DM, Tatsumura Y, Kakai H (2002) Communication between physicians and cancer patients about complementary and alternative medicine: exploring patients’ perspectives. Psychooncology 11: 212220.

42. Shim JM, Schneider J, Curlin FA (2014) Patterns of user disclosure of complementary and alternative medicine (CAM) use. Med Care 52: 704–708. [PubMed: 25025870]

43. Tarn DM, Karlamangla A, Coulter ID, Paterniti DA, Knox L, et al. (2015) A cross-sectional study of provider and patient characteristics associated with outpatient disclosures of dietary supplement use. Patient Educ Couns 98: 830–836. [PubMed: 25865413]

44. Chamberlin SR, Oberg E, Hanes DA, Calabrese C (2014) Naturopathic practice at North American academic institutions: description of 300,483 visits and comparison to conventional primary care. Integr Med Insights 9: 7–15. [PubMed: 24899792]

45. Fleming SA, Gutknecht NC (2010) Naturopathy and the primary care practice. Prim Care 37: 119–136. [PubMed: 20189002]

46. Litchy AP (2011) Naturopathic physicians: holistic primary care and integrative medicine specialists. J Diet Suppl 8: 369–377. [PubMed: 22432775]

47. National Center for Complementary and Integrative Health. “Naturopathy.” Retrieved 8 29, 2019.

48. Jakes D, Kirk R (2015) How and why patients use acupuncture: an interpretive phenomenological study. J Prim Health Care 7: 124–129. [PubMed: 26125058]

49. Blum C, Globe G, Terre L, Mirtz TA, Greene L, et al. (2008) Multinational survey of chiropractic patients: reasons for seeking care. J Can Chiropr Assoc 52: 175–184. [PubMed: 18769601]

50. Cui J, Wang S, Ren J, Zhang J, Jing J (2017) Use of acupuncture in the USA: changes over a decade (2002–2012). Acupunct Med 35: 200–207. [PubMed: 28087523]

51. Bryman A (2012) Social Research Methods. (4th edn), Oxford: Oxford University Press.

52. Morris CA, Avorn J (2003) Internet marketing of herbal products. JAMA 290: 1505–1509. [PubMed: 13129992]

53. Bernard HR (2006) Research Methods in Anthropology. (4th edn), Lanham, MD: AltaMira.

54. Mayring P (2004) Qualitative content analysis. In: Flick U, von Kardorff E, Steinke I, A Companion to Qualitative Research. London: Sage, 266–269.

55. Morse JM (2001) Qualitative verification: building evidence by extending basic findings In: Morse JM, Swanson JM, kuzel Aj, The Nature of Qualitative Evidence. Thousand Oaks, CA: Sage, 203–221.

56. Peng CC, Glassman PA, Trilli LE, Hayes-Hunter J, Good CB (2004) Incidence and severity of potential drug-dietary supplement interactions in primary care patients: an exploratory study of 2 outpatient practices. Arch Intern Med 164: 630–636. [PubMed: 15037491]

57. Sood A, Sood R, Brinker FJ, Mann R, Loehrer LL, et al. (2008) Potential for interactions between dietary supplements and prescription medications. Am J Med 121: 207–211. [PubMed: 18328304]

58. Bush TM, Rayburn KS, Holloway SW, Sanchez-Yamamoto DS, Allen BL, et al. (2007) Adverse interactions between herbal and dietary substances and prescription medications: a clinical survey. Altern Ther Health Med 13: 30–35.

59. Chao MT, Wade C, Kronenberg F (2008) Disclosure of complementary and alternative medicine to conventional medical providers: variation by race/ethnicity and type of CAM. J Natl Med Assoc 100: 1341–1349. [PubMed: 19024232]
60. Howell L, Kochhar K, Saywell R Jr, Zollinger T, Koehler J, et al. (2006) Use of herbal remedies by Hispanic patients: do they inform their physician? J Am Board of Fam Med 19: 566–578. [PubMed: 17090790]

61. Poss J, Pierce R, Prieto V (2005) Herbal remedies used by selected migrant farmworkers in El Paso, Texas. J Rural Health 21: 187–191. [PubMed: 15859058]

62. Rhee TG, Evans RL, McAlpine DD, Johnson PJ (2017) Racial/ethnic differences in the use of complementary and alternative medicine in us adults with moderate mental distress. J Prim Care Community Health 8: 43–54. [PubMed: 27678243]

63. Tarn DM, Guzman JR, Good JS, Wenger NS, Coulter ID, et al. (2014) Provider and patient expectations for dietary supplement discussions. J Gen Intern Med 29: 1242–1249. [PubMed: 24875792]

64. Ahn AC, Ngo-Metzger Q, Legedza AT, Massagli MP, Clarridge BR, et al. (2006) Complementary and alternative medical therapy use among Chinese and Vietnamese Americans: prevalence, associated factors, and effects of patient-clinician communication. Am J Public Health 96: 647–653. [PubMed: 16380575]

65. Oh B, Butow P, Mullan B, Clarke S, Tattersall M, et al. (2010) Patient-doctor communication: use of complementary and alternative medicine by adult patients with cancer. J Soc Integr Oncol 8: 56–64. [PubMed: 20388446]

66. Roberts CS, Baker F, Hann D, Runfola J, Witt C, et al. (2005) Patient-physician communication regarding use of complementary therapies during cancer treatment. J Psychosoc Oncol 23: 35–60. [PubMed: 16618687]
Selected guiding questions for interview.

| Question                                                                 |
|-------------------------------------------------------------------------|
| If you talked about the supplements you are taking during your last visit: |
| What prompted the discussion?                                           |
| What was going on in your mind when you mentioned the supplement(s)?    |
| What kept you from mentioning other supplements you are taking during your last visit? |
| If you did not talk about supplements:                                  |
| Why did you not bring them up?                                          |
| Is there anything that could have prompted you to discuss them?         |
| Under what conditions do you feel it is necessary to discuss dietary supplement use? |
| Under what conditions do you feel it is not necessary to discuss dietary supplement use? |
### Table 2:

Interviewee characteristics.

| Characteristics            | Primary care patients n = 45 | Integrative/naturopathic patients n = 33 | p-value |
|---------------------------|-----------------------------|------------------------------------------|---------|
| Female, frequency (%)     | 28 (62.2)                   | 25 (75.6)                                | 0.20    |
| Age in years, mean (standard deviation) | 48.4 (18.2)                   | 53.8 (13.7)                               | 0.15    |
| Race/ethnicity, frequency (%) |                            |                                          | 0.08    |
| White                     | 17 (37.8)                   | 22 (66.7)                                |         |
| Hispanic                  | 11 (24.4)                   | 2 (6.1)                                  |         |
| Black                     | 7 (15.6)                    | 4 (12.1)                                 |         |
| Asian                     | 4 (8.9)                     | 1 (3.0)                                  |         |
| Multiracial/Other         | 6 (13.3)                    | 4 (12.1)                                 |         |
| Highest level of education, frequency (%) |                |                                          | 0.02    |
| High school or less       | 2 (4.4)                     | 0 (0.0)                                  |         |
| Some college              | 19 (42.2)                   | 6 (18.2)                                 |         |
| College graduate          | 24 (53.3)                   | 27 (81.8)                                |         |
Table 3:

Themes related to disclosure and nondisclosure of dietary supplement use during office visits.

| Domains                      | Themes                        | Disclosure examples                                                                 | Nondisclosure examples                                                                 |
|------------------------------|-------------------------------|-------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|
| Features of the office visit | Interaction during the visit  | Provider inquiry about supplement use (157): He asked me what supplements I was taking. | Provider didn’t ask about supplement use (187): He didn’t specifically ask. |
|                              |                               | Provider inquiry about what a patient is taking (705): She asked me what I take daily, and I told her. | (688): Any time they don’t ask [disclosure is unnecessary]. |
|                              |                               | (671): They always want to know what you are taking besides your medication.         | Topic didn’t come up (198): It just never comes up. |
|                              |                               | Provider didn’t ask about supplement use (187): He didn’t specifically ask.         | (448): It [supplements] just didn’t come up. |
|                              |                               | (688): Any time they don’t ask [disclosure is unnecessary].                         |                                                                                       |
|                              |                               | Topic didn’t come up (198): It just never comes up.                                 |                                                                                       |
|                              |                               | (448): It [supplements] just didn’t come up.                                        |                                                                                       |
|                              | Discussion topic              | Self-care (691): I had not been feeling well, and I said that I had used my herbal remedies, which was Vitamin C and Echinacea. | Supplements unrelated to purpose of visit (672): I really wasn’t there to talk to him about supplements. |
|                              |                               | (708): I mentioned that I was taking these [supplements] in addition to staying away from various foods. | (682): I went to see the doctor about something else. |
|                              |                               | Lab results (802): We were itemizing the chem panel and I started telling her, “Well, I take – I already take a multi.” | Competing demands during visit (151): I was more interested in addressing things that were probably way more important. |
|                              |                               | (560): I was taking a supplement called Coenzyme-A...and it really, really skewed one of my lab results...and I mentioned, “These are what I’m taking”. | (557): There are other things to discuss, and that doesn’t really seem pertinent to any of the problems. |
|                              |                               |                                                                                     | Type of office visit (424): This was more kind of a follow up visit. There was no reason for it to come up. |
|                              |                               |                                                                                     | (363): I [because] it wasn’t a general physical. |
|                              | Visit characteristics         | Before surgery/procedure (172): Before going into surgery, always discuss your supplements. | Not on list to discuss (329): [Spr | |
|                              |                               | (705): If someone’s going to do a brain cat scan on me tomorrow, I think they should know what I have ingested that morning. |         | |
|                              | Type of office visit          | (418): I was going in for a physical and...I let him know I’m taking some Mass XXX. | Provider already knows about supplement (565): [The doctor] already knows that I’m taking all the vitamins and everything because...I usually tell these things to the nurse. |
|                              |                               | (455): If it’s an establishment visit, you definitely want to let your doctor know everything you’re taking. | (511): It’s in my summary, and I don’t think I need to talk about. |
|                              | Organizational and procedural factors |                                                                                     |                                                                                       |
|                              | Patient health and medical care | Concerns about supplement (560): If you’re taking them and not feeling well...you need to bring it up (811): I thought maybe Vitamin C was too much, that’s why it is giving me more: [sic] too often. |                                                                                       |
|                              |                               | Safety concerns (187): I just wanted to make sure [fish oil] was safe. (867): I wanted to know if it was safe or not. |                                                                                       |
|                              |                               | Request advice from provider (329): To ask...whether or not a couple of these supplements I was taking right. |                                                                                       |
| Domains | Themes | Disclosure examples | Nondisclosure examples |
|---------|--------|---------------------|-----------------------|
|         |        | (857): It’s important for me to talk to her about my supplement use because… I want her input. | Sporadic use (362): If you're very sporadic about taking supplements, it's probably not necessary to bother the doctor with that. |
| Circumstances of supplement use | Taking unusual/multiple/mega-dose supplements (363): If I were to go on high potency regimen... then I think I should talk to the doctor. (560): If you thought that you were taking something that may be kind of controversial... you should bring it up. | Change in supplement use (591): I give her information every time I change my supplement list. (618): Every time I have a visit with a doctor, I talk about supplements. Or I talk about any additional supplements. |
| Medication related | Taking prescription medication (329): If you’re on a regular medication, you want to make sure your doctor knows that you’re also on these other things. | Prescribed new medication (110): I would have discussed it if I were being prescribed a new medicine. (158): What made me talk about it [was] … I was kind of concerned about what she was giving me for my acid reflux... would it counteract the enzymes. |
| Medical condition | Having a medical condition (228): Anybody that has any health challenges should disclose. (820): I think with psychiatric conditions it is important. | Good health/fitness (363): If my health is stable and good... I don’t think it has to be brought up. (557): Because we’re healthy. (560): If I go in and my labs are perfect, and everything’s good, I don’t feel the need to discuss it. |
| Provider and patient characteristics | Doctor expertise/knowledge (835): She is a naturopath... so it was a built-in topic. (591): I want them all to know [what I’m taking] because they’re very knowledgeable. | Doctor lack of knowledge (455): I’m sure it wouldn’t hurt [to disclose], but... I would doubt that she would know what they are. Doctor unreceptiveness/disinterest (157): I would never discuss it because they just don’t want to hear about it. (151): I never would even think that a Western doctor would really be that interested. |
| Patient convictions | Important to disclose supplements (688): I think a doctor should know everything that you consume regularly. (705): I feel pretty strongly that she needs to have an up-to-date list of what I’m taking. | Not worth mentioning (234): It’s just something that I don’t think is worth mentioning. Supplements are beneficial/commonplace (816): I didn’t feel like I needed to bring them up because... vitamins and herbs are beneficial. (867): The Emergen-C, I think that’s just a good drink... so I didn’t think anything of it. |
| Patient confidence | | Supplements are equivalent to food (648): Because I figured... everything we eat has vitamins in it anyway. (110): Because... Vitamin C is in most fruit, if not all. I think Vitamin D we get from the sun. Fish oils you get when you eat fish. | Confidence in own knowledge |
| Domains | Themes | Disclosure examples | Nondisclosure examples |
|---------|--------|---------------------|-----------------------|
|         |        |                     | (820): I...am pretty savvy with what I ingest, so I didn’t think [mentioning] it was worthwhile. |
| Did not cross mind |        |                     | (560): I’ve done quite a bit of research in regard to the affect they have on the body... so I’m pretty well educated. |
|         |        |                     | Did not cross mind |
|         |        |                     | (672): It just didn’t occur to me. |

Numbers in parentheses refer to the interviewee ID number.
Table 4:

Generalized Linear Mixed Models for relationship of identified themes on supplement disclosure and nondisclosure (n = 466 supplements).

| Themes related to disclosure                      | Estimate for relationship to supplement disclosure | Standard Error | p-value |
|--------------------------------------------------|----------------------------------------------------|----------------|---------|
| Interaction during visit                         | 1.89                                               | 0.45           | < 0.001 |
| Discussion topic                                 | 2.63                                               | 0.43           | < 0.001 |
| Visit characteristics                            | − 0.65                                             | 1.06           | 0.54    |
| Concerns about supplement                        | 1.22                                               | 0.47           | < 0.01  |
| Circumstances of supplement use                   | − 0.09                                             | 1.00           | 0.93    |
| Medication related                               | 2.79                                               | 0.79           | < 0.001 |
| Medical condition                                | − 1.04                                             | 1.47           | 0.48    |
| Provider characteristics                         | 2.28                                               | 0.66           | < 0.001 |
| Patient convictions                               |                                                    |                |         |

| Themes related to nondisclosure                   | Estimate for relationship to supplement disclosure | Standard Error | p-value |
|--------------------------------------------------|----------------------------------------------------|----------------|---------|
| Interaction during visit                         | − 3.48                                             | 1.07           | < 0.01  |
| Visit characteristics                            | − 3.94                                             | 0.74           | < 0.001 |
| Organizational and procedural factors            | − 3.63                                             | 0.67           | < 0.001 |
| Circumstances of supplement use                   | − 1.85                                             | 0.59           | < 0.01  |
| Medical condition                                |                                                    |                |         |
| Provider characteristics                         | − 1.53                                             | 0.75           | 0.04    |
| Patient convictions                               | − 2.51                                             | 0.69           | < 0.001 |
| Patient confidence                               | − 0.78                                             | 0.63           | 0.02    |
| Did not cross mind                                | − 4.72                                             | 1.19           | < 0.001 |

* reference group = supplement nondisclosure.